Heron Therapeutics (NASDAQ:HRTX - Get Free Report) posted its earnings results on Thursday. The biotechnology company reported $0.02 earnings per share for the quarter, topping analysts' consensus estimates of ($0.03) by $0.05, Zacks reports. The company had revenue of $40.78 million for the quarter, compared to the consensus estimate of $37.37 million. Heron Therapeutics updated its FY 2025 guidance to EPS.
Heron Therapeutics Stock Performance
Shares of NASDAQ:HRTX traded down $0.23 during mid-day trading on Monday, reaching $2.24. 3,230,465 shares of the company's stock were exchanged, compared to its average volume of 1,797,269. Heron Therapeutics has a twelve month low of $1.04 and a twelve month high of $3.93. The firm has a market capitalization of $340.69 million, a price-to-earnings ratio of -12.44 and a beta of 1.60. The business's fifty day moving average price is $1.69 and its 200-day moving average price is $1.71.
Analyst Ratings Changes
Several research firms recently weighed in on HRTX. StockNews.com raised Heron Therapeutics from a "hold" rating to a "buy" rating in a report on Friday. Needham & Company LLC reissued a "buy" rating and set a $4.00 price target on shares of Heron Therapeutics in a research note on Friday.
Check Out Our Latest Analysis on HRTX
Heron Therapeutics Company Profile
(
Get Free Report)
Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
Featured Articles
Before you consider Heron Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Heron Therapeutics wasn't on the list.
While Heron Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
